Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Airpiprazol Depot-Injektionssuspension

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jul 03, 2027 · 308 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Airpiprazol in der Darreichungsform Depot-Injektionssuspension, ATC N05AX12

60/100

Score d'opportunité

PromisingLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or guaranteed minimum volumes; financial return is uncertain.

The open-house model is not subject to procurement law, but the notice includes a voluntary standstill period of 10 day...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive rebate agreements for Aripiprazole depot injection suspension (ATC N05AX12) under §130a Abs. 8 SGB V.
  • All interested pharmaceutical companies can conclude identical, non-negotiable rebate agreements.
Afficher le résumé complet

This is an open-house model (not a competitive procurement) by AOK Bayern to conclude non-exclusive rebate agreements with all interested pharmaceutical companies for the active ingredient Aripiprazole in depot injection suspension (ATC N05AX12). Any eligible pharmaceutical company can join at any time during the contract period (01.09.2025 to 31.08.2027), with the final deadline for signing 03.07.2027. No estimated value is provided. The procedure is not subject to procurement law. Only the structured data and TED XML notice were analyzed; no procurement documents were examined.

Risques

No estimated value or guaranteed minimum volumes; financial return is uncertain.

The open-house model is not subject to procurement law, but the notice includes a voluntary standstill period of 10 day...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer).

Administrative

  • Submit signed and completed self-declaration of reliability.
  • Submit signed contract and annex listing the medicinal products.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria – open-house model.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Airpiprazol Depot-Injektionssuspension

Non-exclusive rebate agreement for Aripiprazole depot injection suspension (ATC N05AX12) with AOK Bayern. Any pharmaceutical company meeting eligibility can join. Contract period 01.09.2025-31.08.2027, with possible termination. No estimated value.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Aug 2025 - Aug 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria – open-house model.

Détails de la procédure

Date de publication
13 Jul 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
456665-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30